Journal list menu
IssueCancer Communications: Volume 45, Issue 1
1-73January 2025
Export Citations
Download PDFs
FEATURED COVER
Cover Image, Volume 45, Issue 1
- First Published: 24 January 2025
The cover image is based on the article Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms by Jiali Yao et al., https://doi.org/10.1002/cac2.12613.
ISSUE INFORMATION
LETTER TO THE JOURNAL
Tumor derived cell-free nucleic acid upregulates programmed death-ligand 1 expression in neutrophil via intracellular Toll-like receptor signaling
- Pages: 4-8
- First Published: 30 October 2024
Wnt/GSK-3β mediates posttranslational modifications of FLYWCH1 to regulate intestinal epithelial function and tumorigenesis in the colon
- Pages: 9-14
- First Published: 30 October 2024
REVIEW
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms
- Pages: 15-42
- First Published: 01 November 2024
RESEARCH HIGHLIGHTS
FOXO1 or not FOXO1: that is the question
- Pages: 43-45
- First Published: 07 November 2024
LETTER TO THE JOURNAL
Discovery of a novel viroid-like circular RNA in colorectal cancer
- Pages: 46-50
- First Published: 09 November 2024
Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes
- Pages: 51-55
- First Published: 11 November 2024
RESEARCH HIGHLIGHTS
Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma
- Pages: 56-57
- First Published: 13 November 2024
LETTER TO THE JOURNAL
Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti-PD-1 therapy
- Pages: 58-62
- First Published: 20 November 2024
EDITORIAL
Anti-tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards
- Pages: 63-67
- First Published: 20 November 2024
LETTER TO THE JOURNAL
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
- Pages: 68-73
- First Published: 24 November 2024
Sign up for email alerts
Tools
More from this journal
Cancer collection based on different tumor types
Information for Authors
Cancer Communications offers waivers to authors for selected high quality articles. For rapid feedback on the potential suitability of an article for waiver, please send a pre-submission enquiry to the editorial office, providing the article title, abstract and a brief cover letter.
Impact Factors in Journal Citation Report (2018, Clarivate) are under the previous journal title Chinese Journal of Cancer.
Archival Content
To browse articles published in the journal prior to March 2015, please visit the Sun Yat-sen University Cancer Center website.
Understanding Open Access
As an open access journal, all articles in Cancer Communications are freely available to read, download and share immediately on publication.
Relevant Open – Access Health Sciences journals
Aging AND Cancer (2020-Present)
Cancer Innovation (2022-Present)
Clinical and Translational Medicine (2012-Present)
MedComm (2020-Present)
MedComm – Oncology (2022-Present)